Viz Ai
Palo Alto, US · Founded 2016 · Delaware corporation · 328 employees on LinkedIn · 13 known investors
Viz.ai uses artificial intelligence to accelerate care coordination in healthcare settings, reducing delays between patients and life-saving treatments. The company transforms clinical workflows to improve patient outcomes.
Also known as Viz.ai · Viz.ai, Inc.
Founders & leadership
Viz Ai was founded in 2016 by Chris Mansi, David Golan, and Dr Chris Mansi.
Board
Investors · 13
Reported raises · per SEC filings
Form D private placements$7.3M disclosed across 2 rounds · 2016–2017
▶$4.8MraisedMay 2017 · 5 investors · Other TechnologyRule 506(b)
- Dror BermanDirector
- Kevin DingDirector
- Chris MansiExecutive Officer, Director
- David GolanDirector
- Offering amount
- $5M
- Amount sold
- $4.8M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$2.5MraisedSep 2016 · 10 investors · Other TechnologyRule 506(b)
- DROR BERMANDirector
- CHRIS MANSIExecutive Officer, Director
- MICHAEL O'DONNELLExecutive Officer
- DAVID GOLANDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Proceeds to insiders
- $64K
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Viz.ai develops an artificial intelligence-based care coordination platform for healthcare organizations. The platform analyzes medical imaging and diagnostic data — including CT scans, EKGs and echocardiograms — to automatically detect suspected diseases and generate real-time insights and automated assessments intended to accelerate diagnosis, streamline clinical workflows and support faster treatment decisions. The company states its platform is driven by more than 50 FDA-cleared AI algorithms.
The core product is marketed as Viz.ai One, an all-in-one care coordination solution. Capabilities are organized into therapeutic-area suites covering neurovascular (Viz Neuro), cardiovascular (Viz Cardio), vascular (Viz Vascular), trauma (Viz Trauma), radiology (Viz Radiology) and pulmonary care (Viz Pulmonary Suite). A real-time communications layer notifies and activates care teams within seconds of a suspected disease detection, accessible on mobile or desktop devices. A separate Viz Life Sciences line develops customized solutions in partnership with pharmaceutical and medical device companies.
Business model
Viz.ai sells software solutions to two customer segments: healthcare providers (hospitals and health systems) and life sciences companies. Provider-facing offerings are packaged as a care coordination platform spanning multiple therapeutic areas and include integration support, implementation experts, a customer success team and 24/7 on-call clinical specialists. For life sciences, the company co-develops customized solutions with pharmaceutical and medical device partners. The sources do not disclose pricing or contract structures.
The sources describe provider solutions and life sciences partnerships but do not state pricing, licensing terms or revenue figures.
Traction
Public evidence of traction in the sources is limited to the company's claim of more than 50 FDA-cleared algorithms, references to clinically validated real-world performance data, and testimonials from clinicians at Cooper University Health Care and Swedish Medical Center/Radiology Imaging Associates in Denver. No customer counts, revenue or volume metrics are disclosed.
Latest developments
The fetched sources contain only the company's current website content describing the Viz.ai One platform and its therapeutic-area suites; no dated recent announcements were available.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Viz.ai positions itself as a care coordination platform provider in AI-assisted medical imaging triage; the sources provide no independent market share or competitive ranking data.
The company emphasizes breadth of regulatory clearance (more than 50 FDA-cleared algorithms), coverage across multiple therapeutic areas within a single platform, and the combination of automated detection with real-time team activation and communications rather than detection alone.
Technology
The platform applies AI algorithms to medical imaging and diagnostic data such as CT scans, EKGs and echocardiograms to autodetect suspected diseases across multiple therapeutic areas in seconds. The company reports more than 50 FDA-cleared algorithms and describes the platform as clinically validated with real-world performance data. Detection triggers automated, real-time alerts and communications that reach clinicians on mobile or desktop devices.
Go-to-market
The company markets separate provider and life sciences solution tracks through its website, offering demos and consultations with experts, and supports deployments with dedicated implementation, customer success and 24/7 on-call clinical specialist teams. Named customer references include clinicians at Cooper University Health Care and Swedish Medical Center in Denver.
Hospitals and health systems and their clinical teams — including neurointerventional surgeons, vascular surgeons, radiologists, trauma and hospital medicine teams — as well as pharmaceutical and medical device companies seeking research and patient-access tools.
Geography
The sources do not specify the company's geographic markets; referenced customer sites are in the United States.
History
The available public source is the company's own website and does not cover the company's history.
Risks & controversies
No risks or controversies are documented in the available sources.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 1
by search overlap
Companies competing with Viz Ai for the same Google search keywords, organic and paid, via search-intersection analysis.
Legal entities · 1
corporate structureIn the news
▸Research sources · 4
primary sources listed
- Viz Aiviz.ai · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Viz Ai do?
- Viz.ai operates an AI-powered care coordination platform with 50+ FDA-cleared algorithms for detecting suspected diseases.
- Who founded Viz Ai?
- Viz Ai was founded by Chris Mansi, David Golan, Dr Chris Mansi in 2016.
- Who are Viz Ai's investors?
- Viz Ai's investors include CRV (Charles River Ventures), Geodesic Capital, Hakluyt Capital, Kleiner Perkins, Scale Venture Partners, Seedcamp, Sozo Ventures, Threshold Ventures and 5 more.
- How much funding has Viz Ai raised?
- Viz Ai has disclosed $7.3M raised across 2 rounds.
- Where is Viz Ai headquartered?
- Viz Ai is headquartered in Palo Alto, US.